Travere Q1 net product sales up 64% to $124.5M; FILSPARI approved for FSGS

Travere Therapeutics, Inc.

2026-Q1 EPS reported -$0.40 vs consensus -$0.27 ▼ miss (-47.7%)

FILSPARI net sales $105.2M (+88% YoY); 993 new PSFs in IgAN during Q1.
FDA approved FILSPARI for FSGS on April 13; first patients treated within a week.
Net loss $37.1M ($0.40/sh) vs $41.2M ($0.47/sh); non-GAAP net income $4.1M ($0.05/sh).
Phase 3 HARMONY of pegtibatinase restarted; first new patient dosed; topline data due 2H 2027.
Cash & equivalents $264.7M as of March 31; $25M milestone from Mirum received in April.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Travere Therapeutics, Inc. reported the quarter ended March 31, 2026 results: revenue $124.5 million, net income Net loss for the first quarter of 2026 was $37.1 million, or $0.40 per basic share, EPS $0.40 per basic share.

Period: the quarter ended March 31, 2026
Revenue: $124.5 million
Net income: Net loss for the first quarter of 2026 was $37.1 million, or $0.40 per basic share
EPS: $0.40 per basic share
Result: reported results

Exact text from the filing

supporting a compelling long-term trajectory for the Company.” Financial Results for the Quarter Ended March 31, 2026 U.S. net product sales for the first quarter of 2026 were $124.5 million, compared to $75.9 million for the same period in 2025. The increase is attributable to growth in sales of FILSPARI. Research and development (R&D) expenses for the first quarter

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Travere Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001438533-26-000041

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.